Cargando…

Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice

BACKGROUND AND AIMS: Bupropion was introduced for smoking cessation following a pivotal trial showing that it gave improved efficacy over the nicotine patch and also suggesting combination treatment was beneficial. We tested in clinical practice for an effectiveness difference between bupropion and...

Descripción completa

Detalles Bibliográficos
Autores principales: Stapleton, John, West, Robert, Hajek, Peter, Wheeler, Jenny, Vangeli, Eleni, Abdi, Zeinab, O’Gara, Colin, McRobbie, Hayden, Humphrey, Kirsty, Ali, Rachel, Strang, John, Sutherland, Gay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282128/
https://www.ncbi.nlm.nih.gov/pubmed/23859696
http://dx.doi.org/10.1111/add.12304
_version_ 1782351078430343168
author Stapleton, John
West, Robert
Hajek, Peter
Wheeler, Jenny
Vangeli, Eleni
Abdi, Zeinab
O’Gara, Colin
McRobbie, Hayden
Humphrey, Kirsty
Ali, Rachel
Strang, John
Sutherland, Gay
author_facet Stapleton, John
West, Robert
Hajek, Peter
Wheeler, Jenny
Vangeli, Eleni
Abdi, Zeinab
O’Gara, Colin
McRobbie, Hayden
Humphrey, Kirsty
Ali, Rachel
Strang, John
Sutherland, Gay
author_sort Stapleton, John
collection PubMed
description BACKGROUND AND AIMS: Bupropion was introduced for smoking cessation following a pivotal trial showing that it gave improved efficacy over the nicotine patch and also suggesting combination treatment was beneficial. We tested in clinical practice for an effectiveness difference between bupropion and nicotine replacement therapy (NRT), whether the combination improves effectiveness and whether either treatment might be more beneficial for certain subgroups of smokers. DESIGN: Open-label randomized controlled trial with 6-month follow-up. SETTING: Four UK National Health Service (NHS) smoking cessation clinics. PARTICIPANTS: Smokers (n = 1071) received seven weekly behavioural support sessions and were randomized to an NRT product of their choice (n = 418), bupropion (n = 409) or NRT plus bupropion (n = 244). MEASURES: The primary outcome was self-reported cessation over 6 months, with biochemical verification at 1 and 6 months. Also measured were baseline demographics, health history, smoking characteristics and unwanted events during treatment. FINDINGS: Abstinence rates for bupropion (27.9%) and NRT (24.2%) were not significantly different (odds ratio = 1.21, 95% confidence interval = 0.883–1.67), and the combination rate (24.2%) was similar to that for either treatment alone. There was some evidence that the relative effectiveness of bupropion and NRT differed according to depression (χ(2) = 2.86, P = 0.091), with bupropion appearing more beneficial than NRT in those with a history of depression (29.8 versus 18.5%). Several unwanted symptoms were more common with bupropion. CONCLUSION: There is no difference in smoking cessation effectiveness among bupropion, nicotine replacement therapy and their combination when used with behavioural support in clinical practice. There is some evidence that bupropion is more beneficial than nicotine replacement therapy for smokers with a history of depression.
format Online
Article
Text
id pubmed-4282128
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-42821282015-01-15 Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice Stapleton, John West, Robert Hajek, Peter Wheeler, Jenny Vangeli, Eleni Abdi, Zeinab O’Gara, Colin McRobbie, Hayden Humphrey, Kirsty Ali, Rachel Strang, John Sutherland, Gay Addiction Research Reports BACKGROUND AND AIMS: Bupropion was introduced for smoking cessation following a pivotal trial showing that it gave improved efficacy over the nicotine patch and also suggesting combination treatment was beneficial. We tested in clinical practice for an effectiveness difference between bupropion and nicotine replacement therapy (NRT), whether the combination improves effectiveness and whether either treatment might be more beneficial for certain subgroups of smokers. DESIGN: Open-label randomized controlled trial with 6-month follow-up. SETTING: Four UK National Health Service (NHS) smoking cessation clinics. PARTICIPANTS: Smokers (n = 1071) received seven weekly behavioural support sessions and were randomized to an NRT product of their choice (n = 418), bupropion (n = 409) or NRT plus bupropion (n = 244). MEASURES: The primary outcome was self-reported cessation over 6 months, with biochemical verification at 1 and 6 months. Also measured were baseline demographics, health history, smoking characteristics and unwanted events during treatment. FINDINGS: Abstinence rates for bupropion (27.9%) and NRT (24.2%) were not significantly different (odds ratio = 1.21, 95% confidence interval = 0.883–1.67), and the combination rate (24.2%) was similar to that for either treatment alone. There was some evidence that the relative effectiveness of bupropion and NRT differed according to depression (χ(2) = 2.86, P = 0.091), with bupropion appearing more beneficial than NRT in those with a history of depression (29.8 versus 18.5%). Several unwanted symptoms were more common with bupropion. CONCLUSION: There is no difference in smoking cessation effectiveness among bupropion, nicotine replacement therapy and their combination when used with behavioural support in clinical practice. There is some evidence that bupropion is more beneficial than nicotine replacement therapy for smokers with a history of depression. BlackWell Publishing Ltd 2013-12 2013-08-28 /pmc/articles/PMC4282128/ /pubmed/23859696 http://dx.doi.org/10.1111/add.12304 Text en © 2013 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Reports
Stapleton, John
West, Robert
Hajek, Peter
Wheeler, Jenny
Vangeli, Eleni
Abdi, Zeinab
O’Gara, Colin
McRobbie, Hayden
Humphrey, Kirsty
Ali, Rachel
Strang, John
Sutherland, Gay
Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice
title Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice
title_full Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice
title_fullStr Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice
title_full_unstemmed Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice
title_short Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice
title_sort randomized trial of nicotine replacement therapy (nrt), bupropion and nrt plus bupropion for smoking cessation: effectiveness in clinical practice
topic Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282128/
https://www.ncbi.nlm.nih.gov/pubmed/23859696
http://dx.doi.org/10.1111/add.12304
work_keys_str_mv AT stapletonjohn randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice
AT westrobert randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice
AT hajekpeter randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice
AT wheelerjenny randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice
AT vangelieleni randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice
AT abdizeinab randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice
AT ogaracolin randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice
AT mcrobbiehayden randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice
AT humphreykirsty randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice
AT alirachel randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice
AT strangjohn randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice
AT sutherlandgay randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice